Antibody News and Research

RSS

An antibody is a blood protein that is produced in response to and counteracts an antigen. Antibodies are produced in response to disease and help the body fight against the particular disease. In this way, antibodies help the body develop an immunity to disease.

Characterization of lab-produced neutralizing antibodies targeting SARS-CoV-2

A new study led by Hans-Martin Jäck of the Friedrich-Alexander University Erlangen-Nuremberg in Germany engineered clusters of neutralizing monoclonal antibodies using a transgenic mouse model. A unique characteristic for the antibodies was the different ways it bound to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the overall reduction in the viral spread for human ACE2.

21 Apr 2021

Researchers identify differences in immune response in asymptomatic versus severe COVID-19 cases

The largest study of its type in the UK has identified differences in the immune response to COVID-19, between people with no symptoms, compared to those suffering a more serious reaction to the virus.

21 Apr 2021

Seroprevalence studies monitoring SARS-CoV-2 among vaccinees require more than spike assays

Researchers in the United States have shown that an antibody test measuring host reactivity to the nucleocapsid protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may better detect natural infection among vaccinated individuals than an assay that measures reactivity to the viral spike protein.

21 Apr 2021

Children develop strong, long-lasting immunity following SARS-CoV-2 infection

Researchers in the UK have conducted a study that may explain why children who become infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) do not generally develop severe coronavirus disease 2019 (COVID-19).

20 Apr 2021

Chronic SARS-CoV-2 infections favor viral adaptation, says study

A new study offers a look at how to keep these hopes alive in the current context of highly infectious variants, which often display immune escape mutations.

20 Apr 2021

Humoral immunity developed by DNA vaccine INO-4800 is effective against SARS-CoV-2 variants

A team of international scientists recently demonstrated that antibodies generated in response to the DNA vaccine INO-4800 can effectively neutralize some of the recently emerged variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), such as G614, 501Y.V1, and 501Y.V2.

20 Apr 2021

Study examines SARS-CoV-2 seropositivity in healthy young adults and risk of reinfection

New research has been published in The Lancet Respiratory Medicine, which focuses on evaluating the effect of SARS-CoV-2 seropositivity on the possibility of developing SARS-CoV-2 infection in a young and healthy population. This study is based on the longitudinal prospective cohort study that involves the COVID-19 Health Action Response for Marines (CHARM).

20 Apr 2021

Can fingerprick blood tests help evaluate antibody response and longevity against SARS-CoV-2 post-vaccination?

To monitor antibody level duration of vaccine-induced immune responses, a team of researchers in the U.S. – at Diacarta, University of California and VA Healthcare System, and the Franciscan University of Steubenville – evaluated the feasibility of using a single drop of fingerstick blood collected with flocked swabs for quantitative antibody response evaluation after COVID-19 vaccination.

20 Apr 2021

Could virosome-based nanovaccines be a promising new approach to preventing viral diseases?

A recent review in the International Journal of Biological Macromolecules provides a novel overview of 'virosome'-based nanovaccine production, its properties, and its application in viral diseases, emphasizing its importance in SARS-CoV-2 vaccine discovery.

20 Apr 2021

Immune tolerance in hemophilia can be modulated by B cell activating factor

A group of scientists have just made a key discovery that could prevent and eradicate immune responses that lead to treatment failure in about one-third of people with severe hemophilia A.

20 Apr 2021

Just one mRNA vaccine dose sufficient for people with prior SARS-CoV-2 infection

A small study, previously posted to the medRiv preprint server in early March, was recently published in the journal Science Immunology. The now peer-reviewed research led by E. John Wherry of the University of Pennsylvania Perelman School of Medicine finds people previously exposed to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) produced a more robust immune response after receiving the first — but not the second mRNA vaccine.

19 Apr 2021

One dose of mRNA vaccine may be sufficient for individuals previously infected with SARS-CoV-2

A recent scientific report from Israel shows how healthcare workers previously infected with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) present with higher Immunoglobulin G (IgG) titers after receiving one dose of Pfizer–BioNTech COVID-19 vaccine in comparison to their fully vaccinated, never-infected counterparts. Conversely, the occurrence of post-vaccination infection does not increase IgG titers.

19 Apr 2021

Researchers reveal long-term kinetics of anti-SARS-CoV-2 antibodies in patient sera

A team of scientists in Germany recently evaluated the specificities and sensitivities of different serological assays for detecting antibodies against SARS-CoV-2.

19 Apr 2021

Antibodies may not inhibit SARS-COV-2 variants from mink

It has been known for about a year that minks can become infected with SARS-CoV-2. The virus had been transmitted from humans to farmed mink and mutated in infected animals.

19 Apr 2021

Obesity, hypertension and smoking linked to lower vaccine-induced antibody production against SARS-CoV-2

In a recent study posted to the medRxiv preprint server, a research group from Italy has demonstrated that the antibody response can be blunted in subjects with certain risk factors shortly after the second dose of mRNA vaccine against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

18 Apr 2021

Novel mRNA delivery vehicle provides alternative to LNPs for SARS-CoV-2 vaccines

Researchers in the United States have developed an alternative messenger RNA (mRNA) delivery platform to the lipid nanoparticles that are currently used in vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19).

18 Apr 2021

FDA revokes EUA for monoclonal antibody therapy bamlanivimab to treat patients with COVID-19

Today, the U.S. Food and Drug Administration revoked the emergency use authorization (EUA) that allowed for the investigational monoclonal antibody therapy bamlanivimab, when administered alone, to be used for the treatment of mild-to-moderate COVID-19 in adults and certain pediatric patients.

17 Apr 2021

Supercomputer simulations illuminate the behavior of dominant G form of SARS-CoV-2

Large-scale supercomputer simulations at the atomic level show that the dominant G form variant of the COVID-19-causing virus is more infectious partly because of its greater ability to readily bind to its target host receptor in the body, compared to other variants.

17 Apr 2021

Studies suggest mRNA COVID-19 vaccine may have reduced efficacy in patients with blood cancer

Two new studies published in Blood suggest that the mRNA COVID-19 vaccine may have reduced efficacy in individuals with chronic lymphocytic leukemia (CLL) and multiple myeloma, two types of blood cancer.

17 Apr 2021

Past COVID-19 infection does not completely protect against reinfection in young people

Although antibodies induced by SARS-CoV-2 infection are largely protective, they do not completely protect against reinfection in young people, as evidenced through a longitudinal, prospective study of more than 3,000 young, healthy members of the US Marines Corps conducted by researchers at the Icahn School of Medicine at Mount Sinai and the Naval Medical Research Center, published April 15 in The Lancet Respiratory Medicine.

17 Apr 2021

Antibody News and Research

Further Reading

Characterization of lab-produced neutralizing antibodies targeting SARS-CoV-2

Researchers identify differences in immune response in asymptomatic versus severe COVID-19 cases

Seroprevalence studies monitoring SARS-CoV-2 among vaccinees require more than spike assays

Children develop strong, long-lasting immunity following SARS-CoV-2 infection

Chronic SARS-CoV-2 infections favor viral adaptation, says study

Humoral immunity developed by DNA vaccine INO-4800 is effective against SARS-CoV-2 variants

Study examines SARS-CoV-2 seropositivity in healthy young adults and risk of reinfection

Can fingerprick blood tests help evaluate antibody response and longevity against SARS-CoV-2 post-vaccination?

Could virosome-based nanovaccines be a promising new approach to preventing viral diseases?

Immune tolerance in hemophilia can be modulated by B cell activating factor

Just one mRNA vaccine dose sufficient for people with prior SARS-CoV-2 infection

One dose of mRNA vaccine may be sufficient for individuals previously infected with SARS-CoV-2

Researchers reveal long-term kinetics of anti-SARS-CoV-2 antibodies in patient sera

Antibodies may not inhibit SARS-COV-2 variants from mink

Obesity, hypertension and smoking linked to lower vaccine-induced antibody production against SARS-CoV-2

Novel mRNA delivery vehicle provides alternative to LNPs for SARS-CoV-2 vaccines

FDA revokes EUA for monoclonal antibody therapy bamlanivimab to treat patients with COVID-19

Supercomputer simulations illuminate the behavior of dominant G form of SARS-CoV-2

Studies suggest mRNA COVID-19 vaccine may have reduced efficacy in patients with blood cancer

Past COVID-19 infection does not completely protect against reinfection in young people

eBook: End-to-end solutions for bispecific antibody development eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo